Humacyte, Inc. (HUMA) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Humacyte (HUMA) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Humacyte is a regenerative-medicine biotech that grows bioengineered, off-the-shelf human blood vessels in a lab, and its lead product Symvess won full FDA approval in December 2024 as the first acellular tissue engineered vessel for extremity vascular trauma. The thesis is that Symvess and a pipeline of additional vascular indications turn a long-running science project into a commercial business. The biggest risks are blunt: revenue is tiny and the commercial ramp is unproven, the company burns cash, has repeatedly raised money by issuing stock, and has flagged substantial doubt about its ability to continue as a going concern. As of October 16, 2026 the stock closed near $0.45, down about 54% in 2026 and about 74% over one year, so this is a speculative early-commercial story.
HUMA stock price
As of 2026-11-16, Humacyte, Inc. (HUMA) last closed at $0.5400, down 52.2% over the past year. Over the past 52 weeks it has traded between $0.3540 and $1.49.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Humacyte, Inc.'s investor relations page. Walnut is informational, not investment advice.
HUMA key stats
At $0.54 on November 16, 2026, Humacyte, Inc. (HUMA) has a market cap of $150M.
- Market cap
- $150M
- Price to book
- 4.8
- Beta
- 2.68
Market cap, P/E and yield are measured at the $0.54 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Humacyte, Inc. (HUMA)?
The last two weeks for Humacyte, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HUMA closed at $0.54 on November 16, 2026, up 18.7% over the past five trading days (from $0.46).
- On November 10, 2026, Humacyte, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 10, 2026, Humacyte, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 10, 2026, BTIG kept its Buy rating and $2.00 target.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Humacyte, Inc. (HUMA) do?
Humacyte, Inc. is a regenerative-medicine company that manufactures bioengineered human tissue. Its core platform grows acellular tissue engineered vessels (ATEVs) by seeding human vascular cells onto a biodegradable scaffold in a bioreactor, then washing the cells away to leave a non-living, off-the-shelf vessel that a surgeon can implant without the immune rejection or wait associated with a patient's own vein. The lead product, Symvess (acellular tissue engineered vessel-tyod), is approved as a vascular conduit for adults with extremity arterial injury who need urgent revascularization to avoid imminent limb loss when a vein graft is not feasible.
The company spent more than a decade in development before the FDA granted full approval of Symvess on December 19, 2024, making it the first product of its kind. Commercial launch began in February 2025 at a list price of about $29,500 per unit, and hospitals work the vessel through Value Analysis Committee review before stocking it. Adoption has been slow to start: in the second quarter of 2026 Humacyte reported only about $0.4 million of revenue against a roughly $36.8 million net loss, and trailing twelve-month revenue was about $2.1 million against a net loss near $97 million. It held about $80 million of cash and about $67 million of debt at June 30, 2026. Management has stated its resources are not enough to fund operations for a full year without stronger Symvess sales or additional financing, and the company has repeatedly issued new shares, including a public offering in June 2026.
The latest commercial update, on October 15, 2026, showed the number of hospitals that have ordered Symvess rising from 34 at the end of Q2 to 49 as of September 30, a 44% increase, with new hospital ordering up sequentially each month of the quarter. Phase 3 V012 results for the vessel in women needing hemodialysis access were accepted as a late-breaking presentation at ASN Kidney Week 2026.
What's driving Humacyte, Inc. (HUMA)?
1. First-mover bioengineered vessel.
Symvess is the first FDA-approved acellular tissue engineered vessel, giving Humacyte a genuinely novel, regulator-validated product in a field where no direct equivalent exists. The vessel is off-the-shelf and resists infection and immune rejection, which matters in trauma where time and graft availability are critical. That first-mover status, plus regenerative-medicine designations on later programs, is the core of the bull case. Whether it translates into durable sales still depends on hospital adoption.
2. Pipeline beyond trauma.
The same ATEV platform is being developed for much larger markets than vascular trauma. Positive Phase 3 dialysis-access (AV) data, including the V007 and V012 studies, support a planned supplemental Biologics License Application, and the company confirmed those filing plans in October 2026. V012 results in women requiring hemodialysis access were accepted for a late-breaking session at ASN Kidney Week 2026. A separate 6mm ATEV for advanced peripheral artery disease holds an RMAT designation. Each approved indication would widen the addressable market well beyond the initial trauma use.
3. Commercial ramp underway.
Humacyte moved from approval to active selling in 2025, building hospital accounts, securing Value Analysis Committee clearances, and beginning to recognize product revenue. Ordering hospitals reached 49 at September 30, 2026, up from 34 three months earlier, and the company is aiming to add 20 new hospitals by year-end. Symvess is priced around $29,500 per unit, so even modest unit volumes can scale revenue meaningfully off a tiny base. Analysts' consensus calls for Q3 2026 revenue of about $0.77 million and roughly $21.7 million for full-year 2027, so the pace of account additions converting to repeat orders is the key metric to watch.
4. Manufacturing platform.
Humacyte operates its own bioreactor-based manufacturing for ATEVs, a hard-to-replicate capability built over many years. Scaling that production to support a commercial launch and multiple future indications is both a moat and an execution challenge. Yield, batch consistency, and the FDA's review of commercial batches all gate how fast the company can supply product. Successful scale-up would support gross margins; problems would constrain the launch.
What are the risks to Humacyte, Inc. (HUMA)?
The risks are substantial and concentrated. The commercial ramp for Symvess is unproven and has started slowly, so revenue remains negligible relative to spending: Q2 2026 revenue was about $0.4 million against a $36.8 million net loss, and the per-share loss of $0.16 missed the $0.10 estimate. Humacyte burns cash heavily, with trailing operating cash outflow near $97 million, and management has disclosed substantial doubt about its ability to continue as a going concern without stronger sales or new financing. Funding that gap has meant repeated stock offerings that dilute existing shareholders, including raises in 2026. The share price, near $0.45, sits below Nasdaq's $1 minimum bid requirement, which could become a listing issue if it persists. The pipeline carries clinical and regulatory risk: planned dialysis-access and peripheral-artery filings could be delayed or rejected. Symvess also carries a boxed warning for graft failure, including rupture. And the company faces competition from established vascular grafts and standard surgical options, plus the broad adoption hurdle of getting hospitals to pay a premium for a new technology.
What is the Humacyte, Inc. (HUMA) forecast?
6 analysts publish price targets on HUMA, averaging $1.62 as of November 2026, or +200.0% against the $0.54 share price on November 16, 2026. The published targets run from $0.50 to $4.00, a wide spread, and the ratings split 4 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full HUMA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is HUMA a buy or a sell?
We give no verdict on Humacyte, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. First-mover bioengineered vessel. Symvess is the first FDA-approved acellular tissue engineered vessel, giving Humacyte a genuinely novel, regulator-validated product in a field where no direct equivalent exists. The most optimistic published target, $4.00, assumes this works close to its best case.
The case against. The risks are substantial and concentrated. The most pessimistic target, $0.50, is roughly what HUMA is worth if this bites instead.
Read the full bull and bear case on HUMA, including what would have to change to break either one. Walnut is not an investment adviser.
Has Humacyte, Inc. (HUMA) split its stock?
No. Humacyte, Inc. (HUMA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Humacyte, Inc. (HUMA) valued?
Market cap, P/E and dividend yield at today's price are in the HUMA key stats above. The business figures below come from Humacyte, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$2.1 million
- Revenue (Q2 2026): ~$0.4 million
- Net loss (TTM / Q2 2026): ~$97 million / ~$36.8 million
- Operating cash used (TTM): ~$97 million
- Cash / debt (Jun 30, 2026): ~$80 million / ~$67 million
- Cash runway: Less than 1 year flagged; going-concern doubt
As of October 2026: An early-commercial biotech like Humacyte cannot be valued on earnings, because there are none; it trades on the option value of a ramping product and an expanding pipeline weighed against cash burn and dilution. At about $0.45 a share the market values the company near $125 million, well below its mid-2026 level, and the mean analyst target of about $1.62 shows how wide expectations run. The relevant questions are how fast Symvess revenue scales toward the cash-burn rate, how much new stock must be issued before that happens, and what the dialysis-access program could be worth if approved; Q3 results are expected around November 12.
Who competes with Humacyte, Inc. (HUMA)?
Regenerative-medicine and vascular tissue peers
Other companies developing engineered tissues, scaffolds, and cell-based vascular or wound therapies compete for the same regenerative-medicine narrative and investor capital, though none has a directly equivalent FDA-approved bioengineered vessel.
Conventional vascular grafts and medtech
Established medtech makers of synthetic (ePTFE/Dacron) grafts and surgical vascular products, alongside the standard of care of a patient's own vein, are what Symvess must displace in trauma and dialysis access.
ETFs and diversified alternatives
Investors seeking biotech exposure without single-stock risk often use broad funds such as the SPDR S&P Biotech ETF (XBI) or iShares Biotechnology ETF (IBB), which spread the speculative risk of early-stage names like HUMA across many holdings.
What stocks are similar to Humacyte, Inc. (HUMA)?
Other names that sit close to HUMA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Humacyte, Inc. (HUMA)
There are three common ways to get HUMA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HUMA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where HUMA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Humacyte, Inc. (HUMA)
Humacyte is a speculative early-commercial biotech built around Symvess, the first FDA-approved bioengineered blood vessel, plus a dialysis-access and peripheral-artery pipeline that could expand the addressable market. It tends to behave like a binary clinical-stage name: the share price reacts to launch traction, trial readouts, and the steady dilution needed to fund cash burn, far more than to current earnings. In October 2026 the company reported a jump in ordering hospitals, but the shares trade below $1 with a market cap near $125 million.
More on Humacyte, Inc. (HUMA)
Whether HUMA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HUMA a buy or a sell?, and where the stock could go from here in the HUMA stock forecast.
For income investors, whether HUMA pays a dividend and how the payout looks is covered in does HUMA pay a dividend? And to weigh HUMA against a peer, read the full side-by-side comparisons: HUMA vs HNGE and HUMA vs BMY.
Wondering how HUMA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Humacyte, Inc.
Ask Walnut's AI anything about HUMA and see how it fits what you own.
FAQ
What does Humacyte do?
+
Humacyte is a regenerative-medicine company that grows bioengineered human blood vessels in the lab. It seeds human cells onto a scaffold in a bioreactor and then removes the cells, leaving an off-the-shelf, non-living vessel surgeons can implant. Its lead product, Symvess, is FDA-approved for extremity vascular trauma, and it is developing the same platform for dialysis access and peripheral artery disease.
What is Symvess?
+
Symvess (acellular tissue engineered vessel-tyod) is Humacyte's lead product and the first FDA-approved bioengineered blood vessel. Approved in December 2024 and launched commercially in February 2025, it is used as a vascular conduit in adults with extremity arterial injury who need urgent revascularization to avoid imminent limb loss when a vein graft is not feasible. It is priced at roughly $29,500 per unit, and 49 hospitals had ordered it as of September 30, 2026.
Does HUMA pay a dividend?
+
No. Humacyte does not pay a dividend. It is an early-commercial biotech that is losing money and reinvesting all available capital into launching Symvess and advancing its pipeline, so any return would have to come from share-price appreciation rather than income.
Is HUMA a good stock?
+
This is descriptive, not advice. The bull case is that Symvess is a first-of-its-kind approved product, hospital ordering accelerated in Q3 2026, and the pipeline could expand into much larger dialysis-access and peripheral-artery markets. The bear case is tiny revenue, heavy cash burn, repeated dilution, a share price below $1, and a stated going-concern doubt. Whether it fits depends on your own goals and risk tolerance, since this is a speculative early-commercial biotech.
Is HUMA a good stock to buy right now?
+
This is informational, not a recommendation. As of October 2026, HUMA is an early-commercial biotech with a slow but accelerating Symvess ramp, a market cap near $125 million, and ongoing financing needs that have led to repeated stock offerings. The price tends to react to launch traction, trial readouts, and dilution rather than current earnings. Walnut provides information, not investment advice.
What is Humacyte's pipeline beyond trauma?
+
Humacyte is applying its acellular tissue engineered vessel platform to dialysis access and peripheral artery disease. Positive Phase 3 dialysis-access results (the V007 and V012 trials) support a planned supplemental FDA filing that the company reconfirmed in October 2026, and V012 data in women were accepted for a late-breaking presentation at ASN Kidney Week 2026. Its 6mm vessel for advanced peripheral artery disease holds a Regenerative Medicine Advanced Therapy designation.
Which ETFs or baskets include HUMA?
+
As a small, speculative biotech, HUMA may appear as a small holding in broad biotech ETFs such as the SPDR S&P Biotech ETF (XBI), which is equal-weighted and tilts toward smaller names, or the iShares Biotechnology ETF (IBB). In Walnut you can also hold HUMA as one constituent in a thematic basket alongside other regenerative-medicine or biotech names to spread single-stock risk.
How did Humacyte do in its latest quarter?
+
In Q2 2026 (quarter ended June 30), Humacyte reported revenue of about $406,000, down from about $495,000 in Q1, and a net loss of about $36.8 million, or $0.16 per share versus a $0.10 estimate. A separate October 15 update said ordering hospitals rose to 49 by September 30. Q3 results are expected around November 12, with consensus revenue near $0.77 million.
How has HUMA stock performed in 2026?
+
As of October 16, 2026, HUMA closed near $0.45, down about 54% year to date, about 74% over one year, and about 24% over the past month. Its 52-week range is roughly $0.34 to $1.90. Several analysts cut price targets in early October, and the mean target is about $1.62 across six analysts.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Humacyte, Inc.'s investor relations page or your broker before making investment decisions.